Compare Stocks: KOD, SMMT, PRAX, and NUVL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KOD Kodiak Sciences	$41.35 +3.4%	$39.10	$8.29 ▼ $47.84	$2.59B	2.21	539,418 shs	747,146 shs
NUVL Nuvalent	$123.96	$123.05	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
PRAX Praxis Precision Medicines	$366.81 -0.4%	$313.35	$37.19 ▼ $388.00	$10.24B	2.78	406,898 shs	262,238 shs
SMMT Summit Therapeutics	$13.35 -4.6%	$14.23	$12.25 ▼ $30.05	$10.65B	-1.23	4.00 million shs	9.74 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KOD Kodiak Sciences	0.00%	-8.86%	+0.24%	+11.70%	+379.70%
NUVL Nuvalent	0.00%	0.00%	0.00%	+21.17%	+58.44%
PRAX Praxis Precision Medicines	0.00%	+1.68%	+19.02%	+7.07%	+647.83%
SMMT Summit Therapeutics	0.00%	-4.37%	-2.98%	-20.87%	-50.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KOD Kodiak Sciences	$41.35 +3.4%	$39.10	$8.29 ▼ $47.84	$2.59B	2.21	539,418 shs	747,146 shs
NUVL Nuvalent	$123.96	$123.05	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
PRAX Praxis Precision Medicines	$366.81 -0.4%	$313.35	$37.19 ▼ $388.00	$10.24B	2.78	406,898 shs	262,238 shs
SMMT Summit Therapeutics	$13.35 -4.6%	$14.23	$12.25 ▼ $30.05	$10.65B	-1.23	4.00 million shs	9.74 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KOD Kodiak Sciences	0.00%	-8.86%	+0.24%	+11.70%	+379.70%
NUVL Nuvalent	0.00%	0.00%	0.00%	+21.17%	+58.44%
PRAX Praxis Precision Medicines	0.00%	+1.68%	+19.02%	+7.07%	+647.83%
SMMT Summit Therapeutics	0.00%	-4.37%	-2.98%	-20.87%	-50.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	16.43% Upside
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$573.05	56.23% Upside
SMMT Summit Therapeutics	2.38	Hold	$24.25	81.61% Upside

Current Analyst Ratings Breakdown

Latest KOD, SMMT, PRAX, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$12.00 ➝ $13.00
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00
8/7/2026	PRAX Praxis Precision Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$323.00 ➝ $362.00
8/6/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/6/2026	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$575.00 ➝ $582.00
8/3/2026	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $66.00
7/29/2026	PRAX Praxis Precision Medicines	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$810.00
7/24/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/24/2026	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $38.00
7/24/2026	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	1,197.82	N/A	N/A	$48.03 per share	7.64
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-247.63%	-82.91%	N/A
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	N/A
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/4/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest KOD, SMMT, PRAX, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KOD Kodiak Sciences	N/A	3.54	3.54
NUVL Nuvalent	N/A	16.14	16.14
PRAX Praxis Precision Medicines	N/A	15.73	15.73
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KOD Kodiak Sciences	89.06%
NUVL Nuvalent	97.26%
PRAX Praxis Precision Medicines	67.84%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
KOD Kodiak Sciences	44.40%
NUVL Nuvalent	5.02%
PRAX Praxis Precision Medicines	3.00%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KOD Kodiak Sciences	90	62.58 million	34.79 million	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

KOD, SMMT, PRAX, and NUVL Headlines

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Here's Why

August 14 at 11:59 AM | marketbeat.com

Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT

August 14 at 3:43 AM | marketbeat.com

Leerink Partners Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Market Perform"

August 14 at 1:54 AM | americanbankingnews.com

Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum?

August 13 at 1:03 AM | kalkinemedia.comK

Summit Therapeutics Inc Share Chat (SMMT.US)

August 12, 2026 | lse.co.uk

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

August 12, 2026 | businesswire.com

Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners

August 12, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Cross Above 50 Day Moving Average - What's Next?

August 12, 2026 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?

August 12, 2026 | marketbeat.com

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

August 7, 2026 | barrons.com

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

August 5, 2026 | finance.yahoo.com

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

August 4, 2026 | benzinga.com

The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT

August 4, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts

August 3, 2026 | marketbeat.com

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

July 31, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

July 30, 2026 | theglobeandmail.com

What is HC Wainwright's Estimate for SMMT FY2026 Earnings?

July 29, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

July 29, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Hits New 12-Month Low - Time to Sell?

July 28, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm

July 27, 2026 | prnewswire.com

SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

July 24, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, SMMT, PRAX, and NUVL Company Descriptions

Kodiak Sciences NASDAQ:KOD

$41.35 +1.37 (+3.43%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$41.40 +0.05 (+0.12%)

As of 08/14/2026 07:34 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$366.81 -1.65 (-0.45%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$370.76 +3.95 (+1.08%)

As of 08/14/2026 07:34 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$13.35 -0.65 (-4.64%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$13.39 +0.04 (+0.30%)

As of 08/14/2026 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, SMMT, PRAX, and NUVL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, SMMT, PRAX, and NUVL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, SMMT, PRAX, and NUVL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, SMMT, PRAX, and NUVL Company Descriptions

Kodiak Sciences NASDAQ:KOD

Nuvalent NASDAQ:NUVL

Praxis Precision Medicines NASDAQ:PRAX

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KOD, SMMT, PRAX, and NUVL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KOD, SMMT, PRAX, and NUVL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KOD, SMMT, PRAX, and NUVL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, SMMT, PRAX, and NUVL Company Descriptions

Kodiak Sciences NASDAQ:KOD

Nuvalent NASDAQ:NUVL

Praxis Precision Medicines NASDAQ:PRAX

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools